Doubling investment into health and medical research and building stronger links between research and healthcare are two of the key the recommendations in the draft McKeon Review into Health and Medical Research released today.
Burnet Institute Director and CEO, and President-elect of the Association of Australian Medical Research Institutes; AAMRI, Professor Brendan Crabb says the review recognises the important connection between research and better health outcomes.
“We applaud the panel’s recommendation to increase public sector investment in research over the next decade – we must continue to invest in our strengths, and Australia is a recognised world leader in health and medical research,” Professor Crabb said.
“The review emphasises that a properly targeted increased investment in research leads to both better health and economic outcomes. We would anticipate that the report will now underpin renewed and ongoing government support for the sector given it highlights the clear public benefits of a strong and globally competitive medical research sector.”
Professor Crabb said he along with medical research institutes across Australia, is looking forward to the final report and the government’s response later this year.
Key points of the McKeon Review Consultation Paper:
Embedding research in healthcare – through increasing capacity in health services/health economics/public health research, committing funds for research by health professionals, and KPIs to drive research in the health care system.
Parity in funding of indirect costs of research at 60 percent of national competitive grants - Full funding of the operational costs of research is critical to the long-term survival and strength of Australian MRIs.
th research, committing funds for research by health professionals, and KPIs to drive research in the health care system.
Initiatives to improve the commercial translation of health and medical research including the Development Block scheme and Translational Development Fund.
Streamlining clinical trial processes and increasing funds for non-commercial clinical trials and infrastructure.
CLICK HERE to download the full report.